Skip to content

SORRENTO THERAPEUTICS, INC.: 10-Q filed 2013-11-14

What SORRENTO THERAPEUTICS, INC. reported in its quarterly report filed 2013-11-14 (fiscal Q3 2013): 30 published measures, 102 facts as tagged in accession 0001193125-13-442213.

This filing

Form
10-Q (quarterly report)
Filed
2013-11-14
Fiscal period
fiscal Q3 2013
Accession
0001193125-13-442213 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All SORRENTO THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-09-3037,982,615USD
At 2012-12-316,781,604USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-09-3030,878,824USD
At 2012-12-316,197,431USD
At 2011-12-314,209,489USD
At 2010-12-315,083,824USD
At 2009-12-313,200,731USD
At 2008-12-31-117,448USD
At 2007-12-31-91,703USD
At 2006-12-31-75,401USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-09-306,429,712USD
At 2012-12-315,091,312USD
At 2012-09-306,445,441USD
At 2011-12-313,466,549USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-07-01 to 2013-09-30-3,356,445USD92
2013-01-01 to 2013-09-30-10,615,396USD273
2006-01-26 to 2013-09-30-21,565,695USD2805
2012-01-01 to 2012-12-31-4,845,308USD366
2012-07-01 to 2012-09-30-1,241,229USD92
2012-01-01 to 2012-09-30-3,090,473USD274
2011-01-01 to 2011-12-31-3,236,491USD365
2010-01-01 to 2010-12-31-1,808,386USD365
2009-01-01 to 2009-12-31-942,266USD365
2008-01-01 to 2008-12-31-25,745USD366
2007-01-01 to 2007-12-31-16,302USD365
2006-01-26 to 2006-12-31-75,801USD340

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-09-30-9,278,452USD273
2006-01-26 to 2013-09-30-18,070,952USD2805
2012-01-01 to 2012-09-30-2,468,243USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-01-01 to 2013-09-30359,327USD273
2006-01-26 to 2013-09-302,081,043USD2805
2012-01-01 to 2012-09-30491,096USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2013-07-01 to 2013-09-3083,791USD92
2013-01-01 to 2013-09-30359,451USD273
2006-01-26 to 2013-09-302,154,977USD2805
2012-07-01 to 2012-09-30134,506USD92
2012-01-01 to 2012-09-30461,790USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-09-3011,361,409USD273
2006-01-26 to 2013-09-3026,862,077USD2805
2012-01-01 to 2012-09-305,938,231USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-01-01 to 2013-09-30-744,557USD273
2006-01-26 to 2013-09-30-2,361,413USD2805
2012-01-01 to 2012-09-30-491,096USD274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-09-301,661,551USD
At 2012-12-311,480,989USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-01-01 to 2013-09-30621,771USD273
2006-01-26 to 2013-09-302,088,410USD2805
2012-01-01 to 2012-09-30290,072USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-07-01 to 2013-09-30-3,306,837USD92
2013-01-01 to 2013-09-30-10,538,090USD273
2006-01-26 to 2013-09-30-21,517,283USD2805
2012-07-01 to 2012-09-30-1,243,347USD92
2012-01-01 to 2012-09-30-3,095,819USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-09-306,873,836USD
At 2012-12-315,251,990USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-07-01 to 2013-09-3051,285USD92
2013-01-01 to 2013-09-3082,975USD273
2006-01-26 to 2013-09-3082,975USD2805

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-09-302,318,471USD
At 2012-12-31584,173USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-09-301,407,516USD
At 2012-12-31439,533USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2013-09-3028,994,423USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2013-07-01 to 2013-09-303,390,628USD92
2013-01-01 to 2013-09-3010,897,541USD273
2006-01-26 to 2013-09-3023,672,260USD2805
2012-07-01 to 2012-09-301,377,853USD92
2012-01-01 to 2012-09-303,557,609USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-07-01 to 2013-09-302,082,252USD92
2013-01-01 to 2013-09-305,621,969USD273
2006-01-26 to 2013-09-3013,825,295USD2805
2012-07-01 to 2012-09-30950,823USD92
2012-01-01 to 2012-09-302,667,347USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-09-3016,479,734shares
At 2012-12-3112,004,687shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-09-3052,442,871USD
At 2012-12-3117,146,530USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2013-09-304,785,320USD
At 2013-02-28875,888USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2013-09-30452,805USD
At 2012-12-3148,625USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2013-09-30102,387USD
At 2012-12-3166,896USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2013-09-30407,560USD
At 2012-12-3180,918USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-07-01 to 2013-09-301,114,621USD92
2013-01-01 to 2013-09-303,752,233USD273
2006-01-26 to 2013-09-308,323,626USD2805
2012-07-01 to 2012-09-30427,030USD92
2012-01-01 to 2012-09-30890,262USD274

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2013-01-01 to 2013-09-30637,648USD273
2006-01-26 to 2013-09-301,116,337USD2805
2012-01-01 to 2012-09-30209,038USD274

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2013-01-01 to 2013-09-30800USD273
2006-01-26 to 2013-09-305,600USD2805
2012-01-01 to 2012-09-30800USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2013-01-01 to 2013-09-306,354,409USD273
2006-01-26 to 2013-09-3021,805,860USD2805
2012-01-01 to 2012-09-305,934,031USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-09-30824,878USD273
2006-01-26 to 2013-09-301,001,824USD2805
2012-01-01 to 2012-09-30169,786USD274

Inspect the source

Entity
SORRENTO THERAPEUTICS, INC. / CIK 0000850261
Captured
SEC response SHA-256
52c2f17674a4b77d02e740899926ba7e57965bff74d27d5e57742ede3dd5745d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000850261.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))